Newer Antibiotics for Carbapenem-Resistant Enterobacteriaceae
Introduction and Mechanisms of Resistance
- Carbapenem-resistant Enterobacterales (CRE) are classified as a World Health Organization (WHO) critical priority and Centers for Disease Control and Prevention (CDC) urgent threat due to high mortality rates in vulnerable pediatric cohorts, including neonates, oncology patients, and transplant recipients,.
- Resistance mechanisms include Non-Carbapenemase-Producing CRE (Extended-Spectrum Beta-Lactamases or AmpC combined with porin loss or efflux pump overexpression) and Carbapenemase-Producing CRE (CP-CRE).
- CP-CRE relies on enzymes categorized by the Ambler classification into Class A (serine carbapenemases like KPC), Class B (metallo-beta-lactamases or MBLs like NDM, VIM, IMP), and Class D (oxacillinases like OXA-48-like enzymes).
- Recent 2024-2026 guidelines de-prioritize older, highly nephrotoxic and neurotoxic polymyxins to salvage therapy.
- Targeted Beta-Lactam/Beta-Lactamase Inhibitors (BL/BLIs) now serve as first-line therapy, strictly guided by rapid molecular diagnostics to identify the precise carbapenemase enzyme.
Genotype-Directed Therapeutic Algorithms
| Carbapenemase Class | Common Enzyme | Preferred Targeted Therapy |
|---|---|---|
| Class A | KPC | Ceftazidime-avibactam (CZA), Meropenem-vaborbactam (MEV), Imipenem-relebactam (IMR). |
| Class B (MBL) | NDM, VIM, IMP | Cefiderocol OR Ceftazidime-avibactam plus Aztreonam,. |
| Class D | OXA-48-like | Ceftazidime-avibactam (CZA). |
Pharmacological Profiles and Pediatric Applications
- Ceftazidime-Avibactam (CZA): Avibactam is a non-beta-lactam inhibitor active against Class A, C, and D enzymes, but lacks in vitro activity against Class B MBLs. It is FDA-approved for pediatric patients aged 3 months and older for complicated intra-abdominal infections and complicated urinary tract infections. Off-label use in neonatal sepsis demonstrates improved survival rates without significant adverse events.
- Meropenem-Vaborbactam (MEV): Vaborbactam is a cyclic boronic acid-based inhibitor specifically engineered to inhibit KPC enzymes. It is increasingly utilized off-label in pediatric intensive care units for KPC-driven bacteremia and severe pneumonia while dedicated pediatric trials are ongoing.
- Imipenem-Cilastatin-Relebactam (IMR): Relebactam protects imipenem from Class A and C enzymes. Its pediatric use is largely restricted to compassionate use protocols for severe KPC infections where CZA is contraindicated.
- Cefiderocol: A first-in-class siderophore cephalosporin that functions as a biological Trojan horse, actively transporting into bacterial cells via iron transport channels. It is highly stable against hydrolysis by Class A, B, C, and D beta-lactamases and is emerging as a critical salvage therapy for children with NDM-producing CRE infections.
- Eravacycline: A synthetic fluorocycline that overcomes common tetracycline resistance mechanisms and exhibits potent activity against KPC, MBL, and OXA-48-producing CRE. Phase 1 pediatric pharmacokinetic trials are underway.
- Plazomicin: A next-generation aminoglycoside engineered to evade aminoglycoside-modifying enzymes, though routine pediatric use is hampered by a lack of established dosing guidelines.
Pharmacokinetic Challenges and Antimicrobial Stewardship
- Critically ill children frequently exhibit augmented renal clearance and an expanded volume of distribution due to capillary leak syndrome.
- Achieving pharmacodynamic targets necessitates extended or continuous intravenous infusions of agents like Ceftazidime-avibactam alongside therapeutic drug monitoring.
- Novel CRE antibiotics are strictly categorized under the WHO Reserve group.
- Implementation requires mandatory pre-authorization by Antimicrobial Stewardship Programs (AMSP) to prevent the rapid emergence of resistance against these final-resort drugs.